BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.69
+0.06 (0.79%)
At close: Nov 6, 2026, 4:00 PM EST
7.71
+0.02 (0.26%)
After-hours: Nov 6, 2026, 7:30 PM EST
BioCryst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 961.51 | 874.84 | 450.71 | 331.41 | 270.83 | 157.17 | |
Revenue Growth | 60.30% | 94.10% | 36.00% | 22.37% | 72.31% | 782.38% |
Cost of Revenue | 210.33 | 183.16 | 185.71 | 216.47 | 259.89 | 216.07 |
Gross Profit | 751.18 | 691.68 | 265.01 | 114.94 | 10.94 | -58.9 |
Selling, General & Admin | 282.42 | 344.37 | 266.29 | 213.72 | 159.37 | 118.82 |
Operating Expenses | 282.42 | 344.37 | 266.29 | 213.72 | 159.37 | 118.82 |
Operating Income | 468.76 | 347.3 | -1.28 | -98.78 | -148.44 | -177.72 |
Interest Expense | -76.81 | -78.87 | -98.52 | -108.24 | -99.09 | -59.29 |
Interest & Investment Income | 10.65 | 10.67 | 14.75 | 15.78 | 5.13 | 0.06 |
Currency Exchange Gain (Loss) | -0.3 | -0.15 | -0.64 | -1.04 | -1.98 | -0.7 |
Other Non Operating Income (Expenses) | 8 | 8.52 | - | - | - | - |
EBT Excluding Unusual Items | 410.3 | 287.47 | -85.69 | -192.28 | -244.38 | -237.65 |
Merger & Restructuring Charges | -60.41 | -6.31 | -1.26 | -3.38 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 |
Gain (Loss) on Sale of Assets | 3.57 | 3.57 | - | - | - | - |
Asset Writedown | - | - | - | -1.55 | - | - |
Other Unusual Items | -10.42 | -17.33 | - | -29.02 | - | 55.84 |
Pretax Income | -354.73 | 267.39 | -86.95 | -226.23 | -244.38 | -181.81 |
Income Tax Expense | 4.92 | 3.53 | 1.93 | 0.31 | 2.73 | 2.25 |
Net Income | -359.66 | 263.86 | -88.88 | -226.54 | -247.12 | -184.06 |
Net Income to Common | -359.66 | 263.86 | -88.88 | -226.54 | -247.12 | -184.06 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 241 | 210 | 207 | 192 | 186 | 179 |
Shares Outstanding (Diluted) | 241 | 219 | 207 | 192 | 186 | 179 |
Shares Change | 15.25% | 5.75% | 7.54% | 3.38% | 3.79% | 7.08% |
EPS (Basic) | -1.49 | 1.26 | -0.43 | -1.18 | -1.33 | -1.03 |
EPS (Diluted) | -1.49 | 1.21 | -0.43 | -1.18 | -1.33 | -1.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 365.85 | 344.9 | -53.14 | -97.31 | -163.2 | -144.54 |
Free Cash Flow Per Share | 1.52 | 1.58 | -0.26 | -0.51 | -0.88 | -0.81 |
Gross Margin | 78.13% | 79.06% | 58.80% | 34.68% | 4.04% | -37.48% |
Operating Margin | 48.75% | 39.70% | -0.28% | -29.81% | -54.81% | -113.07% |
Profit Margin | -37.41% | 30.16% | -19.72% | -68.36% | -91.25% | -117.11% |
Free Cash Flow Margin | 38.05% | 39.42% | -11.79% | -29.36% | -60.26% | -91.97% |
EBITDA | 472.47 | 350.79 | 1.73 | -95.91 | -146.18 | -176.83 |
EBITDA Margin | 49.14% | 40.10% | 0.39% | -28.94% | -53.98% | -112.51% |
D&A For EBITDA | 3.71 | 3.49 | 3.01 | 2.87 | 2.25 | 0.89 |
EBIT | 468.76 | 347.3 | -1.28 | -98.78 | -148.44 | -177.72 |
EBIT Margin | 48.75% | 39.70% | -0.28% | -29.81% | -54.81% | -113.07% |
Effective Tax Rate | - | 1.32% | - | - | - | - |
Revenue as Reported | 961.51 | 874.84 | 450.71 | 331.41 | - | - |
Advertising Expenses | - | 13.82 | 13.57 | 14.4 | 14.89 | 5.71 |